BFC Planning, Inc.’s TG Therapeutics TGTX Stock Holding History

BFC Planning, Inc.’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.6K	Sell	338 -3	-0.9%	-$123	﹤0.01%	2045
2026 Q1	$11.3K	Sell	341 -4	-1%	-$119	﹤0.01%	1989
2025 Q4	$10.3K	Hold	345	–	–	﹤0.01%	2072
2025 Q3	$12.5K	Sell	345 -216	-39%	-$7.12K	﹤0.01%	1803
2025 Q2	$20.2K	Sell	561 -29	-5%	-$1.08K	﹤0.01%	1496
2025 Q1	$23.3K	Buy	590 +34	+6%	+$1.14K	﹤0.01%	1401
2024 Q4	$16.7K	Buy	+556	New	+$16K	﹤0.01%	1539

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

BFC Planning, Inc.'s TGTX Position: Q2 2026 in Review

BFC Planning, Inc. reduced its TG Therapeutics (TGTX) stake by 0.88% in Q2 2026, selling an estimated $123 and leaving 338 shares worth $18.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

BFC Planning, Inc. first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $23.3K in Q1 2025. 434 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

BFC Planning, Inc. held 338 shares of TG Therapeutics worth $18.6K as of Q2 2026.
BFC Planning, Inc. sold 3 TG Therapeutics shares in Q2 2026, an estimated $123.
TG Therapeutics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #2045 holding.
BFC Planning, Inc. first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
BFC Planning, Inc.'s TG Therapeutics position peaked at $23.3K in Q1 2025.
434 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.